• Je něco špatně v tomto záznamu ?

Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer

T. Buchler, A. Poprach, Z. Bortlicek, R. Lakomy, R. Chloupková, R. Vyzula, M. Zemanova, K. Kopeckova, M. Svoboda, O. Slaby, I. Kiss, H. Studentova, J. Hornova, O. Fiala, J. Kopecky, J. Finek, L. Dusek, B. Melichar, . ,

. 2017 ; 15 (6) : e1047-e1053. [pub] 20170629

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010416

Grantová podpora
NV15-34678A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. PATIENTS AND METHODS: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. RESULTS: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference < .001 and .009 for OS difference). CONCLUSION: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010416
003      
CZ-PrNML
005      
20201116155148.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clgc.2017.06.006 $2 doi
035    __
$a (PubMed)28720439
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska, Prague, Czech Republic. Electronic address: tomas.buchler@ftn.cz.
245    10
$a Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer / $c T. Buchler, A. Poprach, Z. Bortlicek, R. Lakomy, R. Chloupková, R. Vyzula, M. Zemanova, K. Kopeckova, M. Svoboda, O. Slaby, I. Kiss, H. Studentova, J. Hornova, O. Fiala, J. Kopecky, J. Finek, L. Dusek, B. Melichar, . ,
520    9_
$a BACKGROUND: Although targeted therapies with inhibitors of the vascular endothelial growth factor (VEGF) are the mainstay of treatment for metastatic renal cell carcinoma, there are limited data on the outcome of patients with long-term response to this treatment. PATIENTS AND METHODS: In a retrospective, registry-based study, patients continuously treated with first-line anti-VEGF agents for at least 24 months were included. In total, 219 patients had evaluable data and were included in the outcome analysis. RESULTS: Median progression-free survival (PFS) after initiation of first-line targeted therapy was 39.7 months (95% confidence interval [CI], 35.9-43.5 months), with 5-year PFS of 34.2% (95% CI, 27.2%-41.2%). Median overall survival (OS) reached 79.1 months (95% CI, 65.2-93.0 months) with the 5-year OS of 62.1% (95% CI, 54.5%-69.7%). In this cohort, 28, 103, and 88 patients achieved complete response (CR), partial response (PR), or stable disease (SD) as the best response, respectively. Median PFS and OS were comparable in patients with PR and SD, but significantly longer in patients with CR (log rank test P value for PFS difference < .001 and .009 for OS difference). CONCLUSION: There are marked differences in PFS and OS between patients who receive long-term anti-VEGF treatment, achieving CR and non-CR as the best clinical response. Patients with non-CR experienced a relatively high progression rate shortly after the landmark time point of 2 years.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory angiogeneze $x terapeutické užití $7 D020533
650    _2
$a bevacizumab $x terapeutické užití $7 D000068258
650    _2
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a nádory ledvin $x farmakoterapie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a niacinamid $x analogy a deriváty $x terapeutické užití $7 D009536
650    _2
$a fenylmočovinové sloučeniny $x terapeutické užití $7 D010671
650    _2
$a pyrimidiny $x terapeutické užití $7 D011743
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sulfonamidy $x terapeutické užití $7 D013449
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
655    _2
$a časopisecké články $7 D016428
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Bortlicek, Zbynek $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Chloupková, Renata $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Vyzula, Rostislav $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Zemanova, Milada $u Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Motol University Hospital and Second Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic.
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Hornová, Jana, $d 1981- $7 xx0224781 $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska, Prague, Czech Republic.
700    1_
$a Fiala, Ondrej $u Department of Oncology, University Hospital, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Kopecky, Jindrich $u University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology, University Hospital, Pilsen, Czech Republic.
700    1_
$a Dusek, Ladislav $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a ,
773    0_
$w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 15, č. 6 (2017), s. e1047-e1053
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28720439 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20201116155146 $b ABA008
999    __
$a ok $b bmc $g 1287901 $s 1007228
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 15 $c 6 $d e1047-e1053 $e 20170629 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741
GRA    __
$a NV15-34678A $p MZ0
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace